Compare Adaptive Biotechnologies Corp (ADPT) vs PubMatic Inc (PUBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs PubMatic Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while PubMatic Inc trades at $12.9 (market cap $619.32M). The key difference: Adaptive Biotechnologies Corp is far larger — about 5.4× PubMatic Inc's market cap. Which is the better fit depends on your goals.
| ADPT | PUBM | |
|---|---|---|
Market Cap | $3.33B | $619.32M |
Sector | Health | Technology |
52-Week High | $22.37 | $13.83 |
52-Week Low | $10.24 | $6.28 |
Enterprise Value | $3.19B | $516.83M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PubMatic trades at $13.32, down 1.7% over 24 hours, with a bullish technical signal from moving averages and a consensus price target of $17. The company reported a net loss of $14.46M in 2025 despite revenue of $282.93M, though it has beaten earnings expectations in recent quarters. Recent news highlights partnerships and product launches, such as the Creator Marketplace and AgenticOS integrations, aimed at driving growth in digital advertising.
The outlook is mixed: analyst sentiment is evenly split between Buy and Hold, with potential upside to the price target, but profitability concerns and a high P/E ratio of 132 pose risks. Investors should weigh the company's innovation in AI-driven ad tech against ongoing losses and competitive pressures in the programmatic advertising space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
